NASDAQ:INDV

Indivior Q3 2026 Earnings Results & Report

Indivior logo
$28.21 +0.06 (+0.21%)
As of 11/4/2026

Indivior beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 29, 2026. The company reported EPS of $1.32 versus the $1.06 consensus estimate, while revenue of $356 million topped the $329.35 million estimate by $26.65 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
9:00 AM ET

Indivior EPS Results

Actual EPS
$1.32
Consensus EPS
$1.06
Beat/Miss
Beat by +$0.26
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Indivior Revenue Results

Actual Revenue
$356 million
Expected Revenue
$329.35 million
Beat/Miss
Beat by +$26.65 million
YoY Revenue Growth
N/A

Indivior Q3 2026 Earnings FAQ

Indivior (NASDAQ:INDV) reported earnings of $1.32 per share for Q3 2026, beating the consensus estimate of $1.06. The report was announced on Thursday, October 29, 2026.

Indivior reported revenue of $356 million for Q3 2026, against a consensus estimate of $329.35 million.

Indivior Earnings Headlines

$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
Indivior Reports Third Quarter 2026 Financial Results
Indivior to Report Third Quarter 2026 Financial Results
See More Indivior Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indivior? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indivior and other key companies, straight to your email.

About Indivior

Indivior (NASDAQ:INDV) is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment.

The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.

Indivior was formed in 2014 when Reckitt Benckiser separated its pharmaceutical business. It serves patients and healthcare providers in the United States and other markets, with a substantial focus on the U.S. addiction-treatment market.

View Indivior Profile